--- title: "Undervalued Penny Stocks To Consider In August 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/296816088.md" description: "The article highlights undervalued penny stocks for August 2026, including Nautilus Biotechnology (NAUT), Sera Prognostics (SERA), and Cloopen Group Holding (RAAS.Y). Despite market volatility, these companies offer growth potential. NAUT and SERA are pre-revenue life sciences firms with strong financial health ratings but face profitability challenges. Cloopen, a cloud communication provider, is unprofitable yet debt-free with improving loss metrics. The piece emphasizes analyzing financial fundamentals while noting the risks associated with small-cap investments." datetime: "2026-08-24T17:21:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296816088.md) - [en](https://longbridge.com/en/news/296816088.md) - [zh-HK](https://longbridge.com/zh-HK/news/296816088.md) generator: "portal-rs" --- # Undervalued Penny Stocks To Consider In August 2026 Over the last 7 days, the U.S. market has dropped by 1.2%, yet it has shown an impressive rise of 18% over the past year, with earnings forecasted to grow annually by 17%. In this context, identifying stocks that combine affordability with growth potential can be particularly appealing to investors. Although 'penny stocks' might seem like a term from a bygone era, they remain relevant as they often represent smaller or newer companies capable of delivering significant returns when backed by strong financials. Let's explore several standout options from the results in the screener. ## Nautilus Biotechnology (NAUT) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the proteome in the United States, with a market cap of approximately $121.47 million. **Operations:** Currently, Nautilus Biotechnology does not report any revenue segments. **Market Cap:** $121.47M Nautilus Biotechnology, with a market cap of approximately US$121.47 million, is a pre-revenue company in the life sciences sector. Despite reporting minimal revenue of US$0.19 million for the first half of 2026 and maintaining guidance of US$0.5 million for the year, it remains unprofitable with significant net losses. The company's experienced management and board are noteworthy assets, but its high share price volatility and negative return on equity present challenges. Nautilus' recent inclusion in multiple Russell indices may enhance visibility among investors despite its current financial hurdles and limited cash runway extending just over a year without further capital infusion. - Click here to discover the nuances of Nautilus Biotechnology with our detailed analytical financial health report. - Gain insights into Nautilus Biotechnology's future direction by reviewing our growth report. NAUT Financial Position Analysis as at Aug 2026 ## Sera Prognostics (SERA) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** Sera Prognostics, Inc. is a women's health company that focuses on discovering, developing, and commercializing blood-based biomarker tests and predictive analytic products in the United States, with a market cap of $84.42 million. **Operations:** The company's revenue is primarily derived from the development and commercialization of its medical diagnostic products, generating $0.07 million. **Market Cap:** $84.42M Sera Prognostics, with a market cap of US$84.42 million and pre-revenue status, remains unprofitable but shows potential through its innovative PreTRM Test, which has demonstrated clinical value in improving neonatal outcomes. Recent findings from the PRIME trial highlight significant reductions in NICU admissions and morbidity among first-time pregnancies. The company's cash runway extends over a year without debt concerns, though insider selling raises caution. Sera's inclusion in Russell indices may boost investor interest despite ongoing financial challenges. The appointment of experienced director Mark Capone could provide strategic guidance as the company seeks broader adoption of its diagnostic solutions. - Unlock comprehensive insights into our analysis of Sera Prognostics stock in this financial health report. - Gain insights into Sera Prognostics' outlook and expected performance with our report on the company's earnings estimates. SERA Debt to Equity History and Analysis as at Aug 2026 ## Cloopen Group Holding (RAAS.Y) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** Cloopen Group Holding Limited offers cloud-based communication solutions in the People’s Republic of China and has a market cap of approximately $127.85 million. **Operations:** Cloopen Group Holding Limited's revenue is primarily derived from three segments: Cloud-Based Contact Center (CN¥219.17 million), Cloud-Based Unified Communications and Collaboration (CN¥162.82 million), and Communication Platform as a Service (CN¥148.67 million). **Market Cap:** $127.85M Cloopen Group Holding Limited, with a market cap of approximately US$127.85 million, operates in the cloud-based communication sector, generating revenue from its Cloud-Based Contact Center (CN¥219.17 million), Unified Communications and Collaboration (CN¥162.82 million), and Communication Platform as a Service (CN¥148.67 million) segments. Despite being unprofitable, the company has reduced losses by 39.4% annually over five years and is debt-free with short-term assets surpassing liabilities significantly. Its management team averages 8.7 years in tenure, indicating seasoned leadership, while its cash runway exceeds three years based on current free cash flow levels without dilution concerns recently impacting shareholders. - Click here and access our complete financial health analysis report to understand the dynamics of Cloopen Group Holding. - Assess Cloopen Group Holding's previous results with our detailed historical performance reports. RAAS.Y Debt to Equity History and Analysis as at Aug 2026 ## Make It Happen - Investigate our full lineup of 314 US Penny Stocks right here. - Ready For A Different Approach? Outshine the giants: these 18 early-stage AI stocks could fund your retirement. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if Nautilus Biotechnology might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [RAASY.US](https://longbridge.com/en/quote/RAASY.US.md) - [NAUT.US](https://longbridge.com/en/quote/NAUT.US.md) - [SERA.US](https://longbridge.com/en/quote/SERA.US.md) ## Related News & Research - [Sera Prognostics says PRIME trial shows PreTRM-guided care cuts preterm births before 32 weeks by over 50%](https://longbridge.com/en/news/296910866.md) - [SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER | SERA Stock News](https://longbridge.com/en/news/296398026.md) - [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/297069793.md) - [REG - HendersonFarE IncLtd - Issue of Equity](https://longbridge.com/en/news/296940787.md) - [REG - AIM - AIM Notice - 26/08/2026](https://longbridge.com/en/news/296999393.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**